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Abstract
Background: Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain
and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the
limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for
alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as
probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously
in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS.
Methods/Design: The current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a
2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups
consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times
a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary
outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The
secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10
weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks).
Discussion: The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination
therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS.
Trial registration: ClinicalTrials.gov NCT01342718.
Background
Irritable bowel syndrome (IBS), a common chronic gastro-
intestinal disorder characterized by abdominal pain and
alteration of bowel habits in the absence of structural
abnormality, has a prevalence of approximately 15% in
western populations [1,2]. Patients with IBS can be classi-
fied by their predominant bowel habits: diarrhea-predomi-
nant IBS (D-IBS), constipation-predominant IBS, or IBS
with alternating bowel movements [3]. Although smooth-
muscle relaxants, bulking agents, and anti-diarrheal agents
are commonly used as conventional IBS treatments, many
IBS patients turn to alternative treatments because of the
lack of therapeutic advantages of these treatments [4].
Therefore, the development of a new therapy is necessary
for IBS patients.
Gwakhyangjeonggisan (GJS; Kkako-shoki-san in Kampo
Medicine; Huoxiang-zhengqi-san in Traditional Chinese
Medicine), which was recorded originally in the famous
ancient herbal formula literature “Formularies of the
Bureau of people’s Welfare Pharmacies”, consists of 13
common crude herbs. GJS contains the chemical ingredi-
ents naringin, hesperidin, thymol, honokiol, and magnolol
[5] and has been shown to protect intestinal barrier func-
tion [6], contract the colonic muscle [7], and regulate
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any medium, provided the original work is properly cited.infectious diarrhea [8]in vivo. In traditional Korean medi-
cine, this herbal formula has long been used for relieving
abdominal pain, diarrhea, and vomiting as an over-the-
counter or prescribed medicine [9-11]. However, there
have been no clinical trials to investigate the efficacy of
GJS in IBS.
Probiotics are defined as viable microorganisms, which
confer potential health benefits on the host when taken
in proper amounts [12]. They are easily available, do not
require a prescription, and are administered extensively
for the relief of abdominal symptoms [13]. According to
a recent systematic review and meta-analysis study, pro-
biotics caused a modest improvement in the overall IBS
symptoms [14]. The rationale for using probiotics for IBS
is based on the assumption that they modify the compo-
sition of the intestinal microflora [15] and regulate intest-
inal permeability by modulating the epithelial tight
junctions [16]. Duolac7S, a probiotic mixture, contains 7
bacterial species including Bifidobacterium, Lactobacillus,
and Streptococcus. Each of these bacterial species is
reportedly beneficial for IBS [17]. Duolac7S has been
approved by the Korean Food and Drug Administration
for restoring the ecological balance of intestinal micro-
flora and improving intestinal symptoms [18]. Although
Duolac7S has been widely used as an over-the-counter
product for IBS-related symptoms, no clinical trials have
investigated the efficacy of Duolac7S on IBS.
Recently, several herbal formulas and probiotics have
been simultaneously administered to IBS patients for
relieving abdominal symptoms [19]. In addition to lack of
clinical evidence for the use of GJS or Duolac7S, the effi-
cacy of their combined treatment for IBS has not been elu-
cidated. Thus, there is a need to evaluate the safety and
efficacy of administration of GJS, Duolac7S, or a combina-
tion therapy as a frequently used treatment for IBS. In the
current trial, we will identify the safety and efficacy of GJS,
Duolac7S, or a combination therapy on D-IBS by evaluat-
ing IBS symptoms and quality of life. To investigate their
mechanisms in humans, intestinal permeability and com-
position of intestinal microbiota will be assessed.
Materials and methods
Objectives
The aims of the study are as follows: (1) to verify the effect
of GJS combined with Duolac7S on D-IBS; and (2) to ana-
lyze mechanisms and establish scientific evidence for the
use of GJS with Duolac7S by investigating changes in
intestinal permeability and the composition of intestinal
microbiota.
Hypothesis
We hypothesize the following possibilities: (1) GJS com-
bined with Duolac7S will show more beneficial effects
on D-IBS symptoms than either GJS or Duolac7S alone;
and (2) after 8 weeks of administration of GJS with
Duolac7S, intestinal permeability will be lowered and
the proportion of lactic acid bacteria in the intestine will
be changed.
Design
The current study will be conducted as a placebo-
controlled and double-blind trial with 60 patients being
randomly allocated to 4 arms. The trial will be implemen-
ted at Kyung Hee University Hospital at Gangdong in
Seoul, Korea.
Participants will be required to pursue a 2-week run-
in (weeks -2 to 0), 8-week administration (weeks 0 to 8),
and a 2-week follow-up period (weeks 8 to 10) and to
record daily symptoms in a diary.
During the administration period, 1 pack 3 times a day
(2 h after each meal) of GJS or its placebo and 1 capsule
2 times a day (2 h after breakfast and dinner) of Duolac7S
or its placebo will be provided for 8 weeks. All partici-
pants will be divided into 4 groups: (1) the real GJS and
real Duolac7S group; (2) the real GJS and placebo Duo-
lac7S group; (3) the placebo GJS and real Duolac7S
group; and (4) the placebo GJS and placebo Duolac7S
group. The flow of the entire trial is shown in Figure 1.
The current study will be performed in accordance with
the standards of the International Committee on Harmo-
nization on Good Clinical Practice and the revised version
of the Declaration of Helsinki. The protocol of the trial
has been approved by the institutional review boards
(IRBs) and ethics committee of Kyung Hee University
Hospital at Gangdong. The permission number of IRBs is
KHNMC-OH-IRB 2010-011, and the protocol identifica-
tion number of ClinicalTrials.gov is NCT01342718.
Written informed consent will be obtained from all parti-
cipants prior to enrollment and patients will be given ade-
q u a t et i m et od e c i d ei ft h e yw i s ht op a r t i c i p a t eb e f o r e
signing the consent form.
Sample size calculation
The present trial has a pilot character of a new therapeu-
tic strategy of GJS and Duolac7S. Similar to the results of
a previous study, 12 participants who complete the study
can be considered minimal clinical significance [20]. The
drop-out ratio is assumed to be 20%. Ultimately, each
group will consist of at least 15 participants so the total
sample size should be more than 60 participants. This
sample size is determined to provide 80% power to
demonstrate the superiority of the study agents com-
pared to placebos and a P-value < 0.05 will be considered
statistically significant.
Inclusion criteria
Patients aged 18-75 years with consistent abdominal
pain and discomfort should meet the Rome III criteria
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be included in the D-IBS type, defined as loose (mushy)
or watery stools ≥ 25% and hard or lumpy stools < 25%
of bowel movements [3]. The Bristol scale, which is a
visual descriptive stool form scale, will be used to assess
stool consistency [21]. Patients should not have had
structural abnormalities in their intestine detected by
colonoscopy in the past 5 years.
Exclusion criteria
Patients who report the following conditions will be
excluded: (1) history of abdominal surgery which was
related to IBS symptoms; (2) alarm symptoms such as
severe weight loss in the past month, melena, and dys-
phagia; (3) gastrointestinal organic lesions such as cho-
langitis, pancreatitis, enteritis, and ulcer; and (4) severe
systemic organ diseases such as cancer. All participants
will have to undergo routine tests of complete blood
count (CBC), kidney function (blood urea nitrogen and
serum creatinine), liver function (serum aspartate transa-
minase and alanine transaminase), thyroid function (thyr-
oid stimulating hormone), serum C-reactive protein
(CRP), and stool occult blood in order to exclude those
who have infection or serious organ diseases. Women
with childbearing potential will be required to have a
negative pregnancy urine test. Patients who have taken
antibiotics, herbal medicine, or probiotics 2 weeks prior
to screening will also be excluded.
Recruitment
Information will be sent by mail to patients with IBS
w h ow e r ep r e v i o u s l yi d e n t i f i e da tt h eK y u n gH e eU n i -
versity Hospital at Gangdong, and public advertisements
will be placed in the newspaper to recruit participants.
Colored fliers, brochures, and banners have been placed
inside the hospital. We also plan to place advertisements
on the homepage of the hospital and the boards of
social networks like Twitter.
Figure 1 Flow chart of trial. D-IBS: Diarrhea-prediminant irritable bowel syndrome. GJS: Gwakhyangjeonggisan. DUO: Duolac7S. GJS-P: Placebo
of Gwakhyangjeonggisan. DUO-P: Placebo of Duolac7S
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Randomization will be performed by an independent
statistician by generating allocation numbers by using a
random number creation program. The investigator will
be notified of the number assigned to a participant via
fax or e-mail.
Blinding
The patients will be blinded to the treatment they are pro-
vided. The investigator, clinical research coordinator, and
clinical pharmacist will also be blinded to randomization.
Only the independent statistician will be associated with
the randomization, and the entire procedure will be moni-
tored by the authorized clinical research organization
(CRO), Marinet Corporation, Seoul, Korea.
Interventions
GJS, a famous herbal formula in Korea, has been tradition-
ally used for managing various gastrointestinal dysfunc-
tions including diarrhea, abdominal pain, and discomfort
[9-11].
The GJS that will be used in this study is a brown, bitter
herbal extract granule (Gwakjungsan granule
®, Hanpoong
Pharm & Food Co., Ltd., Jeonju, Korea) produced in
accordance with the Korean Good Manufacturing Prac-
tice. Gwakjungsan granule
® (GJG), a water-extracted GJS
mixed with starch and lactose, is allowed and regulated by
the Korean Food & Drug Administration. Each GJG con-
tains the 13 herbs listed in Table 1. All herbs will be
obtained from qualified suppliers in Korea and the GJG
will be sealed in opaque aluminum bags. Placebo GJG,
made with cornstarch powder with the same color and
taste as GJG, will be packed identically to the active herbal
formula in opaque aluminum bags with the same labeling
as real GJG. All packages will be dispensed by an indepen-
dent pharmacist in a separate room. Patients will be
requested to dissolve GJG or placebo granules in each
package using water and take them 2 h after each meal.
Voucher specimens of GJG will be retained at the research
laboratory of the manufacturer.
Duolac7S (Cell Biotech Co., Ltd., Gimpo, Korea) is a
probiotic mixture containing multiple strains of 3 viable
bacteria species: 3 strains of Bifidobacterium (B. brevis, B.
lactis and B. longum); 3 strains of Lactobacillus (L. acido-
philus, L. plantarum, and L. rhamnosus); and 1 strain of
Streptococcus (S. thermophilus). Duolac7S will be con-
tained in the capsule form with each capsule containing 5
billion bacteria in the powder form. Placebo Duolac7S, a
powder consisting of cornstarch with the same color and
taste as Duolac7S, will be contained in a capsule identical
to the study agent. Patients will swallow 1 capsule of Duo-
lac7S or placebo 2 h after breakfast and dinner for the
8-week administration period. At the end of the study,
participants will be asked whether the herbal formula or
probiotic that was administered was real or whether it was
a placebo to evaluate the success of blinding.
Compliance will be checked by counting returned GJG
or Duolac7S. A patient’s data will be excluded from per-
protocol analysis unless compliance reaches at least
more than 60% of each GJG and Duolac7S.
All participants will be asked to record any adverse
events in their diary during administration and the follow-
up period. The CBC, CRP, renal function, and liver func-
tion will be assessed to determine the safety of treatments
after the administration period. Analyses will be underta-
ken at an accredited laboratory. All values detected in the
laboratory will be recorded by the investigator in the case
report form.
Rescue therapy and concomitant medications
During the entire clinical trial, patients will be prohib-
ited from taking any kinds of drugs or therapies that
might affect symptoms related to D-IBS. However,
patients are allowed to take a specified medication for
abdominal symptoms based on the doctor’s judgment as
a rescue drug if their D-IBS symptoms are exacerbated
beyond a tolerable level. In such cases, the investigator
will be informed of the rescue drug administration or it
will be documented in their diary.
Patients must report all prescribed and over-the-coun-
ter medications taken during the study in their diaries. If
patients receive antibiotics for acute infections, symptom
data during the time of antibiotic administration and 1
week after completion will be excluded from analysis.
Outcome measurements
Primary outcomes
Adequate relief (AR) will be used as a primary outcome
to evaluate IBS symptom improvement. Patients are
expected to report on a weekly basis their response to
Table 1 Ingredients of herbal formula
(Gwakhyangjeonggisan)
Scientific name Parts of use Gram/day
Agastache rugosa Above-ground parts 1.0
Perilla frutescens Leaves and twigs 1.0
Angelica dahurica Root 1.5
Areca catechu Peel 1.0
Poria cocos Dried core 3.0
Magnolia officinalis Peel 2.0
Atractylodes macrocephala Peel and rhizome 3.0
Citrus unshiu Peel 2.0
Pinellia ternate Stem 3.0
Platycodon grandiflorum Root and peel 1.5
Glycyrrhiza uralensis Rhizome 1.0
Zingiber officinale Rhizome 1.0
Ziziphus Jujuba Fruit 2.0
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adequate relief of your IBS pain and discomfort?” AR
will be measured at the end of each week during run-in,
administration, and follow-up periods. Responders will
be defined as patients reporting AR for at least 50% of
the study weeks, which was applied as a major variable
in previous studies [20,22]. The proportion of respon-
ders, another primary outcome, will be assessed indivi-
dually during run-in, administration, and follow-up
periods.
Secondary outcomes
Patients will be asked to complete a daily diary to evalu-
ate the severity of the individual symptoms (abdominal
pain, abdominal discomfort, bloating, flatulence, urgency,
and mucus in the stool) and the severity of overall symp-
toms on a 100-mm visual analog scale (VAS) during run-
in, administration, and follow-up periods [22]. The VAS
scores are rounded to the nearest integer in millimeters.
Patients will also be requested to fill in a daily diary to
assess stool frequency and bowel functions on the basis
of the consistency defined by the Bristol stool scale [21]
and the ease of passage, as defined by the adjectival scale
(from manual disimpaction to incontinence) [23].
A quality of life measurement for persons with irritable
bowel syndrome (IBS-QoL) is a 34-item questionnaire
assessing the degree to which IBS interferes with the
patient’s quality of life. The IBS-QoL is composed of 8
dimensions, including dysphoria, interference with activ-
ity, body image, health worry, food avoidance, social reac-
tion, sex, and relationships. Each item is evaluated on a
5-point Likert scale with a higher score indicating a bet-
ter quality of life [24]. The IBS-QoL will be filled out at
the administration period baseline (week 0), the adminis-
tration period end (week 8), and the end of the follow-up
period (week 10).
Assessment of intestinal permeability
Intestinal permeability reflects the intactness of the
intestinal mucosal barrier, which regulates the passive
permeation of the luminal contents [25]. It is possible to
assess intestinal permeability by evaluating the urinary
excretion of lactulose and mannitol given orally [26].
Lactulose is only slightly absorbed and serves as a mea-
sure of the mucosal integrity while mannitol is easily
absorbed and serves as a measure of the transcellular
uptake [27]. The lactulose/mannitol (L/M) test is non-
toxic and noninvasive in humans and is a stable measure-
ment that is not affected by gastric emptying, intestinal
motility, and renal function [28]. Therefore, the L/M test
is a relevant method to measure intestinal permeability in
the current trial. An increased ratio of the excretion of
lactulose to mannitol suggests increased intestinal per-
meability [26]. Increased intestinal permeability is
reported in various intestinal diseases associated with
diarrhea such as leaky gut syndrome [25] or IBS [29,30].
The evaluation procedure is as follows: after an over-
night fast, each subject will void to empty his or her blad-
der and then ingest 13.9 g of lactulose together with 5.3 g
of mannitol dissolved in 500 mL of water. Urine will be
collected over the next 8 h in plastic bags. Patients will
drink approximately 2 L of water during the test, and
other foods or liquid will not be allowed. The entire urine
volume will be measured for 8 h and a 45-mL urine sam-
ple will be stored at -70°C until assayed. The urine will be
c o l l e c t e da tt h eb a s e l i n e( w e e k0 )a n da tt h ee n do ft h e
administration (week 8) period.
Pattern analysis of intestinal microbiota
Associations have been observed between IBS patients’
symptoms and the presence or quantities of certain gas-
trointestinal bacteria [31]. In the current study, we will
focus on the change in the composition of the intestinal
microbiota after administration of the study agents. Each
subject will be expected to submit 5 g of fecal samples
for bacteriological studies at the baseline (week 0) and at
the end of the administration (week 8) periods. The sam-
ples will be collected immediately before urine collection
and stored at -70°C prior to analysis. The fecal samples
will be analyzed in a qualified laboratory (Cell Biotech
Co., Ltd., Seoul, Korea) by the denaturing gradient gel
electrophoresis (DGGE) method and real-time polymer-
ase chain reaction (RT-PCR), which is a useful genotypic
technique for detecting changes in the microbiota [32].
Quality control
To maintain the accuracy and quality of the clinical
trial, audits and monitoring will be implemented by the
Marinet Corporation, a CRO located in Seoul, Korea.
Clinical research associates will regularly monitor
whether the clinical trial is proceeding based on the pro-
tocol by checking trial master files, informed consent
forms, case report forms, adverse events, and compli-
ance with study agents.
Statistical analysis
Statistical analysis of all data will be performed by a
specialized statistician in a blind manner. To assess the
efficacy of this trial, both the intention-to-treat and per-
protocol populations will be analyzed. Baseline characteris-
tics will be compared by Pearson’s chi-square test and
analysis of variance (ANOVA). The target variables for
analysis in this study include the following: (1) AR and
proportion of responders (primary outcomes); (2) VAS for
abdominal pain and diarrhea; (3) bowel function scores
(frequency, consistency, and ease of passage); (4) severity
of individual symptoms (abdominal pain, abdominal dis-
comfort, bloating, flatulence, urgency, and mucus in the
stool) and overall symptoms; and (5) IBS-Qol. All values
will be presented as mean ± SEM. Comparison between
the 4 groups will be performed on the basis of repeated
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compare between the baseline and after a certain period in
each group. The analysis for characteristics such as gender
and age between groups will be conducted along with
Pearson’s chi-square test. All statistical analyses of the
data will be performed using the SPSS program, version
16.0 (SPSS Inc., Chicago, IL) and a P value < 0.05 will be
considered statistically significant.
Discussion
Herbal medicine has been considered safe and effective
for various diseases based on clinical experiences accu-
mulated for thousands of years in traditional medicine
and has gained attention as an alternative treatment for
hard-to-cure or cryptogenic diseases such as IBS [33,34].
Despite recent enthusiasm for herbal medicine, there are
only few well-designed randomized controlled trials
related to herbal medicine, and its mechanisms have
been poorly understood. In the current study, we will
evaluate the efficacy of GJS, a representative herbal for-
mula that has long been used for managing diarrhea and
abdominal pain in traditional Korean medicine [9-11]. In
addition, we will evaluate intestinal permeability and the
composition of intestinal microbiota as biomarkers to
assess the efficacy of GJS. The results of these markers
a r ee x p e c t e dt om a k ei tp o s s i b l et oa n a l y z et h em e c h a n -
isms and build up scientific evidences of GJS.
In addition to frequent usage as an herbal formula for
IBS, probiotics are one of the promising agents extensively
used for IBS. Probiotics have shown effects on IBS through
a variety of mechanisms like competing with pathogens for
nutrients and receptors, inducing hydrolysis of toxins and
receptors, inducing production of organic acids, and mod-
ulating nitric oxide synthesis [35]. One notable mechanism
of probiotics is the anti-inflammatory effect [36]. Approxi-
mately 15% of IBS patients may have a persistent mild
inflammatory state resulting in increased intestinal muco-
sal permeability [37]. The following anti-inflammatory
effects of single strains have been reported: Lactobacillus
plantarum demonstrates significant benefits by increasing
interleukin 10 synthesis and secretion in macrophages and
T cells derived from the inflamed colon [38]; and Bifido-
bacterium breve and Streptococcus thermophilus release
metabolites that exert an anti-tumor necrosis factor-alpha
effect capable of crossing the intestinal barrier [39].
Duolac7S, a study agent in the current trial, contains these
types of bacterial species and is expected to have an
anti-inflammatory effect that will improve intestinal
permeability.
Multi-strain probiotics and high-dose probiotics
appear to have greater efficacy than single strains and
relatively low-dose probiotics [40] and several probiotic
mixtures can lead to the improvement of IBS symptoms.
A probiotic mixture of 4 bacterial species (5 × 10
9 CFU
per day) reduced abdominal pain and distension [41].
The probiotic VSL#3, which is a combination of 8
bacterial strains (4.5 × 10
9 C F Up e rd a y ) ,h a ss h o w n
beneficial effects on flatulence and abdominal bloating
[20,22]. Compared to previous study agents, Duolac7S
contains a relatively high dose (1.0 × 10
10 CFU per day)
of probiotics and various types of bacterial species (7
bacterial species). Thus, Duolac7S is anticipated to have
a greater effect on IBS symptoms than other single
strains or low-dose probiotics.
Predominant bowel dysfunctions, including diarrhea and
constipation, can be associated with changes in the intest-
inal bacterial flora. One case-control study reported a
lower concentration of bifidobacteria and a higher concen-
tration of enterobacteriaceae in patients with IBS [42].
Another study using PCR-DGGE showed a higher concen-
tration of coliforms in the IBS patients [43]. A study using
high-throughput 16S ribosomal RNA sequencing demon-
strated greatly reduced numbers of lactobacilli and collin-
sella in stool samples of IBS patients and an especially low
concentration of bifidobacteria in D-IBS compared to
controls [44]. Despite the limitations of these previous stu-
dies such as differing patient groups and the complexity of
the intestinal microbiota, lactobacilli and bifidobacteria
appear to be relatively reduced in patients with IBS. Thus,
we assume that Duolac7S, which contains a large dose of
lactobacilli and bifidobacteria, will modify the patterns of
the intestinal microbiota and have a therapeutic effect on
IBS symptoms and improve intestinal permeability by
strengthening the integrity of the gut barrier.
The current study has several distinctive features. First,
to the best of our knowledge, this will be the first trial to
investigate the efficacy of GJS and Duolac7S combination
therapy on D-IBS. In spite of the beneficial effects of GJS
on IBS in traditional medicine, treatment of IBS by GJS
has not been evaluated in clinical trials. No studies have
targeted Duolac7S, a mixture of 7 lactic acid bacterial
species, as a treatment for D-IBS; however, several stu-
dies have suggested that the individual bacterial species
in Doulac7S and other probiotics mixtures may improve
IBS symptoms. Moreover, GJS and Duolac7S combina-
tion therapy has never been the subject of a previous
study. Thus, it is expected that the present trial will pro-
vide evidence for the effective application of GJS and
Duolac7S combination therapy in D-IBS. Second, the
participants in the current trial will be grouped into 4
arms. Test groups in this study will be divided into 4
arms in order to identify the efficacy of the combination
therapy and to compare each treatment’s effect. Ulti-
mately, the combination therapy of GJS and Duolac7S
are postulated to generate a synergistic effect resulting in
greater improvement of D-IBS symptoms than individual
GJS or Duolac7S treatment. Third, we will conduct ana-
lyses of intestinal permeability and the composition of
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Duolac7S. The urine and stool analysis results could pro-
vide evidence for the combination treatment and the pos-
sible mechanisms might also be investigated.
Although our study has a relatively small sample size
for a pilot study, our trial is considered to have creative
and challenging characteristics and is expected to play
an important role in providing basic clinical data in the
field of herbs and probiotics and developing methodol-
ogy in IBS studies.
Trial status
The study was conceived and designed in 2010. The first
participant was randomized on 25 April 2011. The
recruitment of the study is ongoing.
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